Calculus Capital Limited / Stargrove Pictures Limited UK Creative Content EIS Fund

Hardman & Co

Why invest

Positives

  • Strategy: To invest in a portfolio of unquoted media companies that will generate meaningful IP.

Issues

  • Time to invest: The target time to invest of 15 months is longer than for some other EIS funds.

The Investment Manager

Positives

  • Team: One of the longest standing managers in the VCT/EIS area, Calculus has a highly experienced and stable team.

Issues

  • Past performance: While Calculus has a substantial and credible record from investing in other sectors, this is a new area for the team. However, the addition of Stargrove brings sector experience.

Nuts & bolts

  • Offer period: Closing dates are quarterly on last Fridays of October, January, April and June.
  • Diversification: The aim is to invest in at least six companies.
  • Valuation: Investors will receive valuations twice a year. Industry guidelines will be used, with two auditors examining the figures.

Specific issues

  • Fees: Mixture of direct fees and charged via the investee companies.
  • Performance fee: 20% on gains over a hurdle rate of 1.2x total capital invested.

Risks

  • Risk mitigation: Although a new sector for the Manager, Calculus will use its established investment processes and has brought in a specialist advisor in Stargrove.
  • Target return: Overall, the strategy is medium-risk relative to other EIS/VCT products, with the target capital return of 2.0x towards the top end of what we’d expect for that risk category.

DOWNLOAD THE FULL REPORT

Share on:
Find more news, interviews, share price & company profile here for:

    EDX Medical reports 2025 results and advances in cancer diagnostics

    EDX Medical Group has published its Annual Report for the year ending 31 March 2025, highlighting the development of a new AI-driven prostate cancer test, a £3 million fundraising, expanded European partnerships, and a service agreement with Royal Marsden NHS Foundation Trust.

    Diverse Income Trust reports £257.9m net assets with 4.18% yield

    Diverse Income Trust reported net assets of £257.9 million as of 31 July 2025, with a NAV of 109.08p per share and a share price of 104.00p, reflecting a 4.66% discount. The trust, managed by Gervais Williams and Martin Turner, delivered a 19.42% one-year share price total return and maintains a historic yield of 4.18%.

    Aptamer advances enzyme modulation projects and expands pharma collaboration

    Aptamer Group announced progress on its Optimer® enzyme modulation projects, including a 10-year non-exclusive licensing deal forecast to cover around 15% of annual overheads and further agreements under discussion with global enzyme distributors.

    Structured products fund Volta Finance reports July NAV of €274.2m, performance up 2.5%

    Volta Finance has reported a July net performance of +2.48%, including a dividend of 15.5 cents per share, bringing financial year gains to +13.9%. Net Asset Value stood at €274.2m (€7.49 per share), with strong contributions from CLO equity tranches, which returned +5.2% during the month

    12.2% total return in H1 2025! Global equity income trust GOT delivers

    Global Opportunities Trust reports a 4.0% NAV total return and a 12.2% share price total return for the six months to 30 June 2025, with net assets rising to £110.7 million.

    SAE Renewables rebrands as Ampeak Energy Limited

    Following shareholder approval at its AGM, SAE Renewables (SIMEC Atlantis) has formally changed its name to Ampeak Energy Limited. The move reflects the company’s transition as it advances its flagship AW1 battery storage project, one of the UK’s largest.

      Search

      Search